Oxford researchers have developed a single-shot malaria vaccine using programmable microcapsules that release booster doses ...

Novavax is a leading pharmaceutical company dedicated to creating protein-based vaccines for diseases like COVID-19 and malaria. Learn more about their innovative vaccine development process and ...

A malaria vaccine developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab has been hailed as a possible game-changer in the fight against the deadly parasitic ...

Novavax, Inc. (NASDAQ: ... Our partnership with the University of Oxford and with Serum Institute resulted in the R21 malaria vaccine which is recommended in children as young as 5 months of age.

According to the WHO, there were an estimated 249 million cases of malaria worldwide in 2022, resulting in 608,000 deaths.

Why PfSPZ-LARC2 vaccine matters. Malaria remains a devastating disease, responsible for approximately 600,000 deaths and 263 million cases annually, disproportionately affecting Sub-Saharan Africa.

After combining on the development of five malaria vaccine candidates since 2016, Swedish CDMO Recipharm and the University of Oxford have expanded their collaboration to include additional ...

Why PfSPZ-LARC2 Vaccine Matters. Malaria remains a devastating disease, responsible for approximately 600,000 deaths and 263 million cases annually, disproportionately affecting Sub-Saharan Africa.

At the meeting, Sail will present new preclinical results demonstrating that its AI-driven design of eRNA vaccine candidates encoding a R21-based malaria antigen successfully formed virus-like ...

The agreement involves co-commercializing the COVID-19 vaccine, developing novel COVID-19-Influenza combination vaccines, and developing multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant.

Novavax's stand-alone trivalent flu and dual Covid-19-influenza vaccines had similar immune responses to those seen in other licensed brands, according to phase 3 trial data. The Gaithersburg, Md ...